Definitive Healthcare (NASDAQ:DH) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Several other equities analysts have also issued reports on the company. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Robert W. Baird set a $1.10 price target on shares of Definitive Healthcare in a research report on Friday, May 8th. Barclays decreased their price target on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a report on Monday, March 30th. Bank of America reaffirmed an “underperform” rating and set a $0.70 price objective on shares of Definitive Healthcare in a research note on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Reduce” and a consensus target price of $2.47.

Definitive Healthcare Price Performance

Shares of DH stock opened at $0.76 on Friday. Definitive Healthcare has a 52 week low of $0.62 and a 52 week high of $4.70. The stock has a market capitalization of $80.09 million, a PE ratio of -0.47, a PEG ratio of 10.11 and a beta of 1.33. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. The stock’s fifty day moving average is $0.83 and its 200-day moving average is $1.32.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.The firm had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Equities research analysts expect that Definitive Healthcare will post 0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Raymond James Financial Inc. acquired a new stake in shares of Definitive Healthcare during the 2nd quarter worth about $32,000. State of Alaska Department of Revenue raised its position in Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after purchasing an additional 5,970 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Definitive Healthcare in the fourth quarter valued at about $35,000. Bayesian Capital Management LP bought a new stake in shares of Definitive Healthcare during the second quarter worth $55,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Definitive Healthcare during the third quarter worth about $64,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.